Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 14/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.35 |
| ▸ | CHUK | O15111 | 3/20 | 0.34 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096569 | 0.84 | TTBK1 (0.42) | TTBK1MAP3K14CHUKTTBK2 | |
| SCHEMBL21096566 | 0.83 | TTBK1 (0.59) | TTBK1MAP3K14CHUK | |
| SCHEMBL21096518 | 0.82 | TTBK1 (0.59) | TTBK1MAP3K14TTBK2 | |
| SCHEMBL21096522 | 0.81 | TTBK1 (0.41) | TTBK1MAP3K14CHUKTTBK2 | |
| SCHEMBL21096561 | 0.81 | ADORA2A (0.34) | — | |
| SCHEMBL16610252 | 0.77 | TTBK1 (0.70) | TTBK1MAP3K14TTBK2 | |
| SCHEMBL21096556 | 0.74 | TTBK1 (0.37) | TTBK1CHUK | |
| SCHEMBL21096534 | 0.71 | TTBK1 (0.52) | TTBK1MAP3K14TTBK2 | |
| SCHEMBL16610196 | 0.70 | TTBK1 (0.44) | TTBK1MAP3K14CHUKTTBK2 | |
| SCHEMBL21096545 | 0.69 | ADORA2A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | TTBK1 317/4885MAP3K14 1/4885CHUK 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.